Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Chemotherapy in patients with luminal breast cancer and an intermediate risk recurrence score

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 27.01.20
Views: 127

Prof Joseph Gligorov - Paris-Sorbonne University, Paris, France

Prof Joseph Gligorov speaks to ecancer at the BGICC 2020 conference in Cairo, Egypt about where chemotherapy should be placed in patients with luminal breast cancer and an intermediate risk recurrence score.

He provides further details of this patient population and refers to the results from the TAILORx study, where adjuvant chemotherapy had no effect in this patient group.

Prof Gligorov also mentions that patients who are aged less or equal to 50 years with a risk recurrence score between 16 and 25 may benefit from chemotherapy.

He concludes by stating that patients above the age of 50 should not be given chemotherapy, but younger patients should.

Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation